Gedatolisib is the first approved agent to inhibit class I PI3K isoforms plus both mTOR complexes, addressing a long-standing challenge in comprehensive PI3K/AKT/mTOR pathway blockade. The indication ...

Clinical trials show targeted kinase inhibitors provide high response rates in children with refractory histiocytic disorders ...

Researchers at The University of Texas MD Anderson Cancer Center have created a comprehensive single-cell map of the tumor ...

Background Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers due to its aggressive biology and ...

Northwestern Medicine scientists have uncovered a biological mechanism that helps explain why most patients with glioblastoma ...

Researchers at The University of Texas MD Anderson Cancer Center have discovered that an investigational epigenetic therapy ...

A new review was published in Volume 13 of Oncoscience on May 22, 2026, titled "Adaptor proteins regulating tumor-associated macrophage polarization during cancer progression." ...

UCLA researchers found NDRG1 builds up in old muscle stem cells, slowing repair but boosting survival. Blocking it speeds ...

For decades, fitness culture drew a hard line in the sand. You were either a strength athlete or an endurance athlete. Cardio was thought to destroy muscle mass, while heavy lifting was blamed for ...

Individual differences in toddler temperament—including activity, emotionality, sociability, and shyness—are influenced in part by genetic variation. Some of these genetic differences also overlap ...

Detailed price information for Quince Therapeutics Inc (QNCX-Q) from The Globe and Mail including charting and trades.

Dose-optimization data from the Phase 1 study expected Q3 2026 to support Phase 2 proof-of-concept initiation in ADPKD in Q4 2026JERSEY CITY, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc.